Login to Your Account



Stressgen Sells Bioreagents Unit To Better Focus On Lead Product

By Aaron Lorenzo


Friday, April 15, 2005
Concentrating its efforts on its lead drug, HspE7, Stressgen Biotechnologies Corp. agreed to divest its bioreagents business in a move that adds a bit of capital to its coffers. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription